KIDS · Orthopediatrics Corp - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $236.35M | $204.73M | $148.73M | $122.29M | $98.05M | $71.08M |
| Cost of Revenue | $63.69M | $56.13M | $37.48M | $31.63M | $24.65M | $16.05M |
| Gross Profit | $172.66M | $148.60M | $111.25M | $90.66M | $73.40M | $55.03M |
| R&D | $9.10M | $11.03M | $10.20M | $8.01M | $5.54M | $5.27M |
| SG&A | $119.83M | $102.79M | $75.42M | $59.38M | $46.06M | $38.32M |
| Total Operating Expenses | $211.90M | $183.61M | $138.00M | $116.06M | $91.43M | $81.79M |
| D&A | $21.12M | $19.08M | $17.39M | $13.10M | $10.68M | $8.01M |
| Operating Income | ($39.24M) | ($35.01M) | ($26.75M) | ($25.40M) | ($18.02M) | ($26.75M) |
| Interest Expense | $27.0K | $35.0K | $56.0K | - | - | $3.41M |
| Income Tax | $460.0K | ($4.11M) | ($338.0K) | ($4.95M) | ($1.13M) | ($723.0K) |
| Net Income | ($39.65M) | ($37.82M) | ($20.97M) | $1.26M | ($16.26M) | ($32.94M) |
| EPS - Basic | ($1.69) | ($1.64) | ($0.92) | $0.06 | ($1.82) | - |
| EPS - Diluted | ($1.69) | ($1.64) | ($0.92) | $0.06 | ($1.82) | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $19.56M | $43.82M | $31.05M | $10.46M | $7.64M | $28.76M |
| Accounts Receivable | $53.84M | $42.36M | $34.62M | $24.80M | $17.94M | $17.21M |
| Inventory | $133.79M | $117.00M | $105.85M | $78.19M | $57.57M | $52.99M |
| Accounts Payable | $18.79M | $8.91M | $12.65M | $11.15M | $9.32M | $10.04M |
| Current Assets | $256.42M | $237.17M | $226.50M | $226.72M | $133.65M | $158.43M |
| Total Assets | $508.63M | $473.21M | $438.75M | $427.73M | $304.27M | $320.41M |
| Current Liabilities | $46.20M | $33.96M | $41.67M | $30.87M | $29.71M | $35.03M |
| Long-term Debt | $99.82M | $72.96M | $9.91M | $763.0K | $907.0K | $1.04M |
| Total Liabilities | $162.03M | $118.64M | $61.72M | $49.08M | $78.91M | $85.64M |
| Stockholders' Equity | $346.60M | $354.57M | $377.02M | $378.65M | $225.37M | $234.77M |
| Retained Earnings | ($275.21M) | ($235.56M) | ($197.74M) | ($176.77M) | ($178.03M) | ($161.77M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($4.85M) | ($27.05M) | ($27.05M) | ($21.77M) | ($13.06M) | ($18.53M) |
| Investing Cash Flow | ($43.63M) | ($13.16M) | $41.68M | ($113.37M) | ($7.41M) | ($69.69M) |
| Financing Cash Flow | $23.98M | $53.13M | $7.30M | $135.97M | $6.0K | $46.73M |
| CapEx | $11.11M | $14.26M | $16.88M | $10.03M | $8.10M | $10.50M |
| Free Cash Flow | ($15.96M) | ($41.31M) | ($43.92M) | ($31.80M) | ($21.17M) | ($29.03M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 73.1% | 72.6% | 74.8% | 74.1% | 74.9% | 77.4% |
| Operating margin | -16.6% | -17.1% | -18.0% | -20.8% | -18.4% | -37.6% |
| EBITDA margin | -7.7% | -7.8% | -6.3% | -10.1% | -7.5% | -26.4% |
| Net margin | -16.8% | -18.5% | -14.1% | 1.0% | -16.6% | -46.3% |
| Free cash flow margin | -6.8% | -20.2% | -29.5% | -26.0% | -21.6% | -40.8% |
| FCF / Net income | 0.40 | 1.09 | 2.09 | -25.28 | 1.30 | 0.88 |
| R&D / Revenue | 3.9% | 5.4% | 6.9% | 6.6% | 5.7% | 7.4% |
| SG&A / Revenue | 50.7% | 50.2% | 50.7% | 48.6% | 47.0% | 53.9% |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -7.8% | -8.0% | -4.8% | 0.3% | -5.3% | -10.3% |
| Return on equity | -11.4% | -10.7% | -5.6% | 0.3% | -7.2% | -14.0% |
| Return on invested capital | -6.9% | -6.5% | -5.5% | -5.3% | -6.3% | -9.0% |
| Liquidity | ||||||
| Current ratio | 5.55 | 6.98 | 5.44 | 7.34 | 4.50 | 4.52 |
| Quick ratio | 2.65 | 3.54 | 2.90 | 4.81 | 2.56 | 3.01 |
| Cash ratio | 0.42 | 1.29 | 0.75 | 0.34 | 0.26 | 0.82 |
| Leverage | ||||||
| Debt / Equity | 0.29 | 0.21 | 0.03 | 0.00 | 0.00 | 0.00 |
| Debt / Assets | 0.20 | 0.15 | 0.02 | 0.00 | 0.00 | 0.00 |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | -1453.3x | -1000.3x | -477.7x | - | - | -7.8x |
| Equity multiplier | 1.47 | 1.33 | 1.16 | 1.13 | 1.35 | 1.36 |
| Liabilities / Assets | 0.32 | 0.25 | 0.14 | 0.11 | 0.26 | 0.27 |
| Efficiency | ||||||
| Asset turnover | 0.46 | 0.43 | 0.34 | 0.29 | 0.32 | 0.22 |
| Inventory turnover | 0.48 | 0.48 | 0.35 | 0.40 | 0.43 | 0.30 |
| Days sales outstanding | 83d | 76d | 85d | 74d | 67d | 88d |
| Days inventory outstanding | 767d | 761d | 1031d | 902d | 853d | 1205d |
| Days payable outstanding | 108d | 58d | 123d | 129d | 138d | 228d |
| Cash conversion cycle | 742d | 778d | 993d | 848d | 781d | 1065d |
| Valuation | ||||||
| P / E | - | - | - | 662.2x | - | - |
| P / B | 1.2x | 1.5x | 2.0x | 2.2x | 4.8x | - |
| P / S | 1.8x | 2.6x | 5.0x | 6.8x | 11.0x | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | 15.4% | 37.6% | 21.6% | 24.7% | 37.9% | -2.0% |
| Revenue CAGR (3y) | 24.6% | 27.8% | 27.9% | 19.0% | 19.4% | 24.0% |
| Revenue CAGR (5y) | 27.2% | 23.1% | 20.9% | 26.8% | - | - |
| Gross profit growth (YoY) | 16.2% | 33.6% | 22.7% | 23.5% | 33.4% | 0.8% |
| Operating income growth (YoY) | -12.1% | -30.9% | -5.3% | -40.9% | 32.6% | -194.8% |
| Net income growth (YoY) | -4.8% | -80.3% | - | - | 50.6% | -139.9% |
| EPS growth (YoY) | -3.0% | -78.3% | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | 61.4% | 5.9% | -38.1% | -50.2% | 27.1% | 1.9% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -2.2% | -6.0% | -0.4% | 68.0% | -4.0% | 64.9% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$236.35M totalTraumaand Deformity$166.30M · 70.4%
Spine$66.05M · 27.9%
Sports Medicine And Other$4.00M · 1.7%
Geographic
$236.35M totalUS$186.40M · 78.9%
Non Us$49.95M · 21.1%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
0.96
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
4/9
Neutral
- ✗Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- ✗Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- ✓Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing ORTHOPEDIATRICS CORP against the 5 most active filers in the same SIC group.